IDVZ - ETF AI Analysis
Top Page
Opal International Dividend Income ETF (IDVZ)
IDVZ, the Opal International Dividend Income ETF, has a solid overall rating, supported by strong holdings like TSMC and AstraZeneca, which benefit from robust financial performance, positive earnings calls, and strategic growth in advanced technologies and healthcare. Other key positions such as GSK, TotalEnergies, and Reckitt Benckiser add to the fund’s quality through steady growth, attractive dividends, and supportive technical trends, while weaker names like British American Tobacco and Petrobras introduce some risk due to earnings volatility, revenue pressures, and bearish or uncertain momentum. The main risk factor is the fund’s exposure to specific sectors like energy and tobacco, where regulatory and profitability challenges can create added volatility.
IDVZ vs. SPDR S&P 500 ETF (SPY)
- AUM
- 202.60M
- Region
- Global Ex-U.S.
- Expense Ratio
- 0.75%
- Beta
- 0.39
- Issuer
- Polen
- Inception Date
- Dec 26, 2024
- Dividend Yield
- 3.05%
- Asset Class
- Equity
- Index Tracked
- MSCI ACWI ex USA High Dividend Yield
IDVZ Summary
The Opal International Dividend Income ETF (IDVZ) tracks the MSCI ACWI ex USA High Dividend Yield index, focusing on companies outside the U.S. that pay relatively high dividends. It holds well-known international names like TSMC and ASML, along with firms in defensive areas such as consumer staples, health care, and utilities. Investors might consider IDVZ if they want regular income from dividends and broader global diversification beyond the U.S. stock market. A key risk is that international stocks and high-dividend companies can still fall in value, so the ETF’s price and income can go up and down with global markets.
How much will it cost me?
This ETF has an annual expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 invested. That’s higher than the average ETF cost because it focuses on a specialized, high-dividend international strategy rather than a simple, broad market index.
What would affect this ETF?
IDVZ could benefit if global interest rates fall or stabilize, making its international high-dividend stocks more attractive, especially in defensive, healthcare, and technology sectors that tend to hold up well in mixed economic conditions. On the other hand, rising rates, stricter regulations on energy and tobacco names like Petrobras and British American Tobacco, or economic slowdowns outside the U.S. could pressure dividends and share prices across its global ex-U.S. holdings.
IDVZ Top 10 Holdings
IDVZ leans heavily on a mix of European banks, energy giants, and healthcare leaders to power its dividend story. Petrobras and TotalEnergies have been rising, giving the fund a strong tailwind from the energy patch, while TSMC adds a steady tech angle tied to global chip demand. On the flip side, consumer name Reckitt Benckiser and utility player Enel are losing steam, and Sanofi has been lagging, tempering overall momentum. With holdings spread across non-U.S. markets, the ETF offers global ex-U.S. income with a noticeable tilt toward financials, energy, and healthcare.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 PBR | Petroleo Brasileiro SA- Petrobras | 4.74% | $9.60M | $157.59B | 118.41% | 69Neutral |
 RBGLY | Reckitt Benckiser Group | 4.12% | $8.35M | $46.79B | -8.80% | 78Outperform |
 RHHBY | Roche Holding | 3.52% | $7.14M | $376.98B | 35.69% | 74Outperform |
 ENLAY | Enel SpA Unsponsored ADR | 3.47% | $7.04M | $102.42B | 4.57% | 71Outperform |
 IMBBY | Imperial Brands | 3.42% | $6.94M | $28.41B | -4.78% | 74Outperform |
 FR:TTE | TotalEnergies SE | 3.33% | $6.75M | EUR 178.44B | 50.82% | 78Outperform |
 GSK | GlaxoSmithKline | 3.21% | $6.51M | $100.19B | 15.70% | 77Outperform |
 BTI | British American Tobacco | 3.17% | $6.43M | $126.23B | 18.24% | 59Neutral |
 TSM | TSMC | 2.89% | $5.86M | $1.92T | 42.74% | 81Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
IDVZ Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDVZ, the sentiment is Positive. The current price of 33.96 is above the 20-day moving average (MA) of 33.38, above the 50-day MA of 33.87, and above the 200-day MA of 33.79, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 57.63 is Neutral, neither overbought nor oversold. The STOCH value of 89.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDVZ.
IDVZ Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IDVZ | $33.96 | $36.00(6.01% Upside) | $202.60M | 0.75% | 65Neutral |
 SCHY | $33.03 | $35.44(7.29% Upside) | $2.67B | 0.08% | 62Neutral |
 FDV | $34.30 | $35.81(4.41% Upside) | $998.19M | 0.50% | 72Outperform |
 FDD | $19.05 | $21.44(12.57% Upside) | $892.40M | 0.56% | 61Neutral |
 DWX | $47.06 | ― | $516.19M | 0.45% | 57Neutral |
 VDI | $34.98 | $40.59(16.04% Upside) | $16.00M | 0.39% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IDVZ | Opal International Dividend Income ETF | 33.96 | 4.25 | 14.32% | |
| SCHY | Schwab International Dividend Equity ETF | 33.03 | 5.63 | 20.56% | |
| FDV | Federated Hermes U.S. Strategic Dividend ETF | 34.30 | 6.40 | 22.96% | |
| FDD | First Trust Stoxx European Select Dividend Index Fund | 19.05 | 3.79 | 24.84% | |
| DWX | SPDR S&P International Dividend ETF | 47.06 | 5.40 | 12.96% | |
| VDI | Virtus International Dividend ETF | 34.98 | 5.48 | 18.56% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.